Inclusion Criteria:

- Newly diagnosed metastatic prostate cancer within 3 months prior to randomization
with histologically or cytologically confirmed adenocarcinoma of the prostate without
neuroendocrine differentiation or small cell histology

- Distant metastatic disease documented by positive bone scan or metastatic lesions on
computed tomography (CT) or magnetic resonance imaging (MRI) scan

- At least 2 of the following high-risk prognostic factors: Gleason score of >=8;
presence of 3 or more lesions on bone scan; presence of measurable visceral
(excluding lymph node disease) metastasis on CT or MRI scan

- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2

- Adequate hematologic, hepatic, and renal function

- Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

- Active infection or other medical condition that would make prednisone use
contraindicated

- Any chronic medical condition requiring a higher systemic dose of corticosteroid than
5 mg prednisone per day

- Pathological finding consistent with small cell carcinoma of the prostate

- Known brain metastasis

- Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate
cancer (the following exception are permitted): up to 3 months of androgen
deprivation therapy (ADT) with lutenizing hormone releasing hormone agonists or
orchiectomy with or without concurrent anti-androgens prior Cycle 1 Day 1; patients
may have one course of palliative radiation or surgical therapy to treat symptoms
resulting from metastatic disease if it was administered at least 28 days prior to
Cycle 1 Day 1); all adverse events associated with these procedures must be resolved
at least to Grade 1 by Cycle 1 Day 1

- Uncontrolled hypertension (systolic blood pressure >=160 mmHg or diastolic BP >=95
mmHg; patients with a history of hypertension are allowed provided blood pressure is
controlled by anti-hypertensive treatment)

- Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding
disorders secondary to hepatic dysfunction

- History of adrenal dysfunction

- Clinically significant heart disease as evidenced by myocardial infarction, or
arterial thrombotic events or history of cardiac failure in the past 6 months, severe
or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease

- Atrial fibrillation or other cardiac arrhythmia requiring pharmacotherapy

- Other malignancy (within 5 years), except non-melanoma skin cancer

- Administration of an investigational therapeutic or invasive surgical procedure (not
including surgical castration) within 28 days of Cycle 1 Day 1 or currently enrolled
in an investigational study

- Any condition or situation which, in the opinion of the investigator, would put the
patient at risk, may confound study results, or interfere with the patient's
participation in this study